Sector Overview
The Healthcare sector has seen steady filing activity over the past 12 months, with companies across the industry reporting on evolving market conditions and strategic initiatives. Annual 10-K filings from the sector's largest companies reveal a mix of operational improvements and forward-looking investments aimed at maintaining competitive positioning.
Quarterly 10-Q filings have highlighted ongoing adjustments to macroeconomic conditions, including interest rate sensitivity and supply chain dynamics. Several companies have disclosed material changes in their risk factors, reflecting the sector's adaptation to regulatory developments and shifting demand patterns.
Key Themes
- Companies adjusting strategies in response to macroeconomic conditions
- Increased disclosure around risk factors and regulatory compliance
- Capital allocation shifting toward long-term strategic investments
- Operational efficiency initiatives featuring in management discussions
Updated Jan 2025 · Based on filings from top Healthcare companies
Company Rankings
| # | Ticker | Company | Industry | Market Cap * | Filings |
|---|---|---|---|---|---|
| 1 | LLY | ELI Lilly & Co | Pharmaceutical Preparations | $1.1T | 422 |
| 2 | JNJ | Johnson & Johnson | Pharmaceutical Preparations | $621.2B | 519 |
| 3 | ABBV | AbbVie Inc. | Pharmaceutical Preparations | $503.3B | 281 |
| 4 | UNH | UnitedHealth Group Inc | Hospital & Medical Service Plans | $374.3B | 665 |
| 5 | MRK | Merck & Co., Inc. | Pharmaceutical Preparations | $369.8B | 465 |
| 6 | AMGN | Amgen Inc | Biological Products, (No Diagnostic Substances) | $237.0B | 548 |
| 7 | GILD | Gilead Sciences, Inc. | Biological Products, (No Diagnostic Substances) | $190.4B | 485 |
| 8 | ABT | Abbott Laboratories | Pharmaceutical Preparations | $173.9B | 470 |
| 9 | PFE | Pfizer Inc | Pharmaceutical Preparations | $170.1B | 539 |
| 10 | VRTX | Vertex Pharmaceuticals Inc | Pharmaceutical Preparations | $132.9B | 466 |
| 11 | BMY | Bristol Myers Squibb Co | Pharmaceutical Preparations | $124.9B | 572 |
| 12 | CVS | CVS Health Corp | Retail-Drug Stores and Proprietary Stores | $119.5B | 580 |
| 13 | MDT | Medtronic plc | Electromedical & Electrotherapeutic Apparatus | $119.0B | 207 |
| 14 | MCK | McKesson Corp | Wholesale-Drugs, Proprietaries & Druggists' Sundries | $118.4B | 568 |
| 15 | SYK | Stryker Corp | Surgical & Medical Instruments & Apparatus | $114.2B | 436 |
| 16 | HCA | HCA Healthcare, Inc. | Services-General Medical & Surgical Hospitals, NEC | $99.5B | 681 |
| 17 | MRNA | Moderna, Inc. | Biological Products, (No Diagnostic Substances) | $98.1B | 156 |
| 18 | ELV | Elevance Health, Inc. | Hospital & Medical Service Plans | $94.1B | 551 |
| 19 | MMM | 3M Co | Surgical & Medical Instruments & Apparatus | $90.1B | 627 |
| 20 | REGN | Regeneron Pharmaceuticals, Inc. | Pharmaceutical Preparations | $82.9B | 451 |
| 21 | CI | Cigna Group | Hospital & Medical Service Plans | $80.4B | 180 |
| 22 | COR | Cencora, Inc. | Wholesale-Drugs, Proprietaries & Druggists' Sundries | $65.0B | 603 |
| 23 | BSX | Boston Scientific Corp | Surgical & Medical Instruments & Apparatus | $64.5B | 610 |
| 24 | AFL | Aflac Inc | Accident & Health Insurance | $60.2B | 433 |
| 25 | CAH | Cardinal Health Inc | Wholesale-Drugs, Proprietaries & Druggists' Sundries | $59.6B | 556 |
| 26 | BDX | Becton Dickinson & Co | Surgical & Medical Instruments & Apparatus | $52.9B | 638 |
| 27 | MDLN | Medline Inc. | Surgical & Medical Instruments & Apparatus | $47.5B | 20 |
| 28 | ONC | BeOne Medicines Ltd. | Pharmaceutical Preparations | $44.0B | 351 |
| 29 | BIIB | Biogen Inc. | Biological Products, (No Diagnostic Substances) | $35.6B | 449 |
| 30 | CNC | Centene Corp | Hospital & Medical Service Plans | $34.7B | 541 |
| 31 | ZTS | Zoetis Inc. | Pharmaceutical Preparations | $32.9B | 262 |
| 32 | DXCM | Dexcom Inc | Surgical & Medical Instruments & Apparatus | $30.3B | 389 |
| 33 | ALNY | Alnylam Pharmaceuticals, Inc. | Pharmaceutical Preparations | $30.1B | 394 |
| 34 | DGX | Quest Diagnostics Inc | Services-Medical Laboratories | $26.4B | 460 |
| 35 | GH | Guardant Health, Inc. | Services-Medical Laboratories | $22.4B | 147 |
Showing 1–25 of 35
Trending 8-K Filings
Medline Inc. 8-K Report, Regulation FD Disclosure (Oct 21, 2026)
Medline Inc. (MDLN) has announced a voluntary field action involving the discontinuation and market exit of all Medline Brand beds, including homecare, bariatric, and long-term care beds, along with associated accessories. This strategic move impacts the Front Line Care product category within the Medline Brand segment. The company reported that the affected products generated approximately $60 million in net sales for the twelve months ended June 27, 2026. Medline currently estimates the total costs associated with this action, including product discontinuation, inventory impairment, disposal costs, and customer credits, to be up to $220 million. These costs are anticipated to be recognized in fiscal years 2026 and 2027 and will be excluded from Adjusted EBITDA. Despite these significant costs, Medline does not expect this action to materially impact its full-year 2026 financial results or its previously issued guidance.
Elevance Health, Inc. 8-K Report, Financial Results (Oct 21, 2026)
Elevance Health, Inc. (ELV) has reported its third quarter 2026 financial results, demonstrating a slight increase in operating revenue to $50.4 billion, up 0.7% year-over-year. The company's performance exceeded expectations, leading to an upward revision of its full-year 2026 guidance for both diluted EPS and adjusted diluted EPS. This positive outlook is supported by improved operating performance and a notable net non-operating benefit recognized in the quarter. The company highlighted increased operating cash flow and continues to invest in capabilities aimed at enhancing the member experience, strengthening its competitive position, and driving long-term growth. The Health Benefits segment saw revenue growth driven by premium yields and service fees, although membership declined in key areas like Medicare Advantage and Medicaid. Conversely, the Carelon segment, encompassing CarelonRx and Carelon Services, experienced robust revenue and operating gain growth, underscoring the strength of its pharmacy and services offerings.
ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 21, 2026)
Abbott Laboratories (ABT) reported strong third-quarter 2026 results, with total reported sales increasing by 14.5% and comparable sales growing by 7.0%. The company reaffirms its full-year 2026 adjusted diluted earnings per share (EPS) guidance of $5.50 to $5.55, tightening the range. This performance was driven by broad-based growth across its key business segments, including Diagnostics and Medical Devices, with notable contributions from new product approvals and market expansions. The report also details significant progress in product innovation and regulatory approvals, including the FDA approval of Libre® Duo, a dual glucose-ketone sensor, and the CE Mark for the Amulet 360™ Left Atrial Appendage Occluder. These advancements, coupled with reaffirmed financial guidance, suggest continued positive momentum for Abbott Laboratories heading into the final quarter of the year.
Cencora, Inc. 8-K Report, Financial Results (Oct 21, 2026)
Cencora, Inc. (COR) announced a significant strategic move via an 8-K filing on October 21, 2026, revealing its definitive agreement to acquire American Oncology Network, Inc. (AON) for an enterprise value of $2.4 billion. This acquisition is poised to bolster Cencora's position in supporting community oncology by integrating AON's physician-led network, which spans over 350 providers across 21 states, into Cencora's existing MSO platform. The company also updated its fiscal year 2026 financial expectations, projecting adjusted diluted earnings per share (EPS) to be at least $17.90, aligning with the higher end of its previous guidance. This updated outlook reflects the strong performance in Cencora's U.S. Healthcare Solutions segment. The acquisition of AON is anticipated to be accretive to Cencora's adjusted diluted EPS in the second year post-closing, signaling a long-term value creation strategy.
ABBOTT LABORATORIES 8-K Report, Corporate Update (Oct 21, 2026)
Abbott Laboratories (ABT) announced its intention to separate its global Nutrition business into an independent, publicly traded company. This strategic move aims to unlock distinct growth and value-creation opportunities for both the standalone Nutrition entity and the remaining Abbott healthcare business. The new Nutrition company is projected to have approximately $8.5 billion in annual sales and will focus on the rapidly growing healthy nutrition market with iconic brands like Similac, PediaSure, and Ensure. Following the separation, Abbott will continue as a diversified healthcare leader with approximately $42 billion in sales, concentrating on its higher-growth, innovation-driven portfolio in medical devices, diagnostics, and established medicines. The separation is anticipated to be completed by the end of 2027 and is structured as a tax-free distribution of shares to Abbott shareholders, who will then own stakes in both entities. This move is expected to allow for more aligned capital allocation and distinct strategic focus for each business.
3M CO 8-K Report, Financial Results (Oct 20, 2026)
3M Company reported strong third-quarter 2026 results, exceeding expectations and leading to an upward revision of its full-year Earnings Per Share (EPS) guidance. The company announced GAAP sales of $6.6 billion, a 1.0% increase year-over-year, with adjusted sales growing 3.3%. Significantly, GAAP EPS surged by 70% to $2.63, and adjusted EPS grew by 12% to $2.50, demonstrating improved profitability. The strong performance was underpinned by robust operating margins, with adjusted operating margin reaching 26.2%, up 110 basis points. The company also reported solid cash flow generation, with adjusted free cash flow of $1.2 billion for the quarter. Strategic partnerships, including an expanded relationship with Amazon for data center products and collaborations in advanced materials and display technologies, highlight 3M's focus on innovation and future growth drivers.
VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Oct 20, 2026)
Vertex Pharmaceuticals Incorporated (VRTX) announced a significant addition to its Board of Directors on October 20, 2026, with the appointment of Daniel Brennan. This appointment increases the size of the Board from ten to eleven members. Mr. Brennan brings a wealth of financial expertise, having served as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation until his retirement in June 2025, and holding various senior finance roles there for many years prior. His extensive background in financial leadership is expected to be a valuable asset to Vertex's strategic and financial oversight. In addition to his extensive corporate finance experience, Mr. Brennan has a strong track record of public company board service, currently sitting on the boards of Waters Corporation and Madrigal Pharmaceuticals, and previously serving on Nuance Corporation's board. His appointment to the Audit and Finance Committee will further strengthen the board's financial governance. The company also disclosed that Mr. Brennan received a $400,000 restricted stock unit award upon joining, which is set to vest in October 2027, aligning his interests with long-term shareholder value.
Medtronic plc 8-K Report, Executive Changes (Oct 19, 2026)
Medtronic plc (MDT) filed an 8-K on October 19, 2026, detailing significant corporate governance and strategic updates. The report announces the appointment of Michael Marinaro to the newly expanded role of President, Medtronic, effective October 14, 2026. This promotion includes increased responsibilities, such as oversight of Greater China operations, and is accompanied by a substantial compensation package, reflecting his expanded influence within the company. The filing also confirms the successful completion of Medtronic's separation from MiniMed Group, Inc., finalized on October 15, 2026, through an exchange offer. Furthermore, the 8-K provides the voting results from Medtronic's Annual General Meeting held on October 15, 2026. Key outcomes include the re-election of all twelve director nominees, ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2027, and shareholder approval for executive compensation. The meeting also saw shareholders renew the Board's authority to issue shares and opt out of pre-emption rights, as well as authorize overseas market purchases of Medtronic ordinary shares. These developments signal both leadership continuity and strategic repositioning for Medtronic.
3M CO 8-K Report, Regulation FD Disclosure (Oct 19, 2026)
3M Company announced on October 19, 2026, a significant expansion of its strategic commercial relationship with Amazon.com, Inc. This collaboration is underscored by the issuance of a warrant to an Amazon subsidiary, granting them the right to purchase over 3.16 million shares of 3M common stock at a price of $164.89 per share over seven years. This equity component is directly tied to Amazon's future purchases of 3M's optical connectivity and data center products, with the majority of shares vesting upon Amazon reaching $6 billion in cumulative payments for these products.
Medline Inc. 8-K Report, Executive Changes (Oct 15, 2026)
Medline Inc. (MDLN) filed an 8-K report on October 15, 2026, disclosing a significant change in its Board of Directors. Joseph P. Baratta, a board member, has announced his resignation, which will be effective as of December 31, 2026. This departure is directly linked to his previously announced exit from Blackstone Inc. While the company expresses gratitude for Mr. Baratta's service, investors should note that his resignation is not attributed to any disagreements concerning Medline's operations, policies, or practices. This information is crucial for understanding board composition and potential influences on corporate strategy moving forward, especially given the timing with his departure from Blackstone.
Frequently Asked Questions
What companies are in the Healthcare sector?
The Healthcare sector includes a range of publicly traded companies that file regular reports with the SEC. These filings, including annual 10-K reports and quarterly 10-Q reports, provide comprehensive data on financial performance, risk factors, and strategic direction for companies operating in this industry.
What types of SEC filings are common in the Healthcare sector?
Companies in the Healthcare sector typically file 10-K annual reports with full financial statements, 10-Q quarterly updates, and 8-K reports for material events. Annual 10-K filings are the most comprehensive, containing management discussion, risk factors, audited financials, and business segment breakdowns.
How can I analyze Healthcare sector trends using SEC filings?
SEC filings provide valuable data for analyzing Healthcare sector trends. Key areas to review include revenue growth rates across companies, changes in risk factor disclosures that signal emerging concerns, capital expenditure patterns indicating investment priorities, and management discussion sections that provide forward-looking commentary on industry conditions.
How often do Healthcare companies file reports with the SEC?
Public companies in the Healthcare sector file 10-K annual reports within 60 days of their fiscal year-end and 10-Q quarterly reports within 40 days of each quarter-end (for large accelerated filers). 8-K current reports are filed within four business days of material events such as acquisitions, leadership changes, or significant financial developments.
Updated Jan 2025 · Based on SEC filings from Healthcare companies